Skip to main content
News

Class I Recall Issued for ICU Medical Potassium Chloride Injection Due to Labeling Error

Edited by 

Key Clinical Summary

  • Product recall: ICU Medical’s Potassium Chloride Injection 20 mEq/50 mL (lot #1030613; NDC 0990-7077-14) is under a Class I nationwide recall initiated October 29, 2025.
  • Reason for recall: Overwrap labeling error may misidentify the product as 10 mEq instead of 20 mEq, posing risk for dosing inaccuracies in critical-care settings.
  • Scope: 21 696 units distributed US-wide; recall is voluntary and ongoing, with facility notifications issued by letter.

A nationwide Class I drug recall has been issued for Potassium Chloride Injection, 20 mEq in 50 mL flexible containers manufactured by ICU Medical, Inc and distributed by Otsuka ICU Medical LLC. The affected product (NDC 0990-7077-14) is a highly concentrated electrolyte solution commonly used in acute-care settings, particularly for critical potassium replacement. The recall covers 21 696 units from lot #1030613, which carries an expiration date of September 30, 2026. The recall was voluntarily initiated on October 29, 2025, with notifications sent by letter to customers, and the US Food and Drug Administration (FDA) officially designated the recall as Class I on November 24, 2025—its most serious classification.

According to the updated FDA Enforcement Report, the recall stems from a labeling error on the product’s overwrap, which may incorrectly list the strength as 10 mEq instead of the actual 20 mEq concentration. This discrepancy creates a significant risk of underdosing or incorrect dose calculation, particularly in high-acuity environments where rapid and precise electrolyte management is critical. Although the inner container is correctly labeled, the overwrap error poses enough potential for clinical confusion to warrant the highest-level recall.

The recall remains ongoing, and distribution of the affected lot extended nationwide throughout the United States. As the recalling firm, Otsuka ICU Medical LLC of Austin, Texas, is coordinating product removal while communicating corrective actions to health care facilities. Potassium Chloride Injection is indicated for the treatment and prevention of hypokalemia, especially in patients requiring controlled intravenous replacement, such as those with severe potassium depletion, cardiac arrhythmias, or conditions requiring intensive electrolyte management.